

# Improved Performance of Waters Alliance HPLC System for System Suitability Results of Area RSD for Eight Challenging Pharmacopoeial and Non-Pharmacopoeial Assay Methods

Dilshad Pullancheri, Chirag Dholakiya, and Dr. Padmakar Wagh  
Applications Laboratory, Waters India Pvt. Ltd., India

## APPLICATION BENEFITS

- Improved performance of Waters® Alliance® HPLC System with 100 µL syringe
- Addresses the system suitability criteria of area precision
- Alliance HPLC System is a reliable and robust instrument that can be used for routine quality control analysis

## WATERS SOLUTIONS

[Waters Alliance HPLC System](#)

[Alliance 100 µL Syringe](#)

[APC Reservoir Caps](#)

[LCGC Certified Waters Vial](#)

## KEYWORDS

Pharmaceutical assay method, Alliance HPLC System, improved performance, system suitability, area precision, 100 µL syringe, self sealing septa, APC reservoir cap

## INTRODUCTION

HPLC has been established as a gold standard in the pharmaceutical industry. The main purposes for using HPLC are for identifying, quantifying, and purifying the individual components of the mixture. HPLC plays an important and critical role in the field of pharmaceutical industries and analysis, since it is used to test the products and to detect the raw ingredient used to make them i.e., qualitative and quantitative analysis. Moreover, the importance of HPLC uses in these fields falls under the stringent regulations established by the U.S. Food and Drug Administration (FDA). This obligates all pharmaceutical companies to detect the quality of their products by using the HPLC system before allowing them to sell it in the global market. The pharmaceutical products are evolving day by day and at the same time regulatory demands are increasing too; at times this poses challenges for HPLC and meeting the criteria of system suitability. It is important to understand the regulation and find a solution to address such requirements.

In this experiment, eight challenging pharmacopoeial and non-pharmacopoeial assay methods as listed in Table 1 were selected based on their injection volume, either 5 or 10 µL, which is lower than typical HPLC injection volume in combination with 100% organic solvent as diluent. Lower injection volume and 100% organic solvent as diluent poses a unique challenge of area precision in HPLC for extended sequence due to longer run time and/or several batches needed to be run back-to-back. All three combinations explained above can make the relative standard deviation for standard and bracketing standard injections area values run out of acceptance window leading to reanalysis.

Table 1. List of eight methods selected for analysis.

Sr. no.	Compound name	Method reference	Diluent	Injection volume (μL)	% RSD limit for area
1	Clopidogrel Bisulfate	USP	Methanol	10	1.0
2	Doxorubicin Hydrochloride	USP	Methanol	10	2.0
3	Galantamine HBr	USP	Methanol	10	2.0
4	Irbesartan	USP	Methanol	10	2.0
5	Olmesartan	Inhouse*	Acetonitrile	10	2.0
6	Clomipramine Hydrochloride	USP	Methanol	10	2.0
7	Aspirin	USP	Acetonitrile:Formic acid (99:1)	10	2.0
8	Dipyridamole	Inhouse*	Methanol	5	5.0

\*USP Pharmacopoeial Method is used as a reference.

In this paper, we have demonstrated the improved performance of Alliance HPLC System with appropriate syringe, sample vials, reservoir caps, and recommended method settings for meeting the relative standard deviation system suitability requirements of the selected eight molecules.

## THE SOLUTION

For increased injection volume accuracy, Alliance HPLC System was configured with 100 μL syringe. As all the selected methods contain 100% organic solvent as diluent, sample vials with specific self sealing septa were used to avoid evaporation and pressurization of the vials, vial caps were screwed only up to resistance. The syringe draw rate in instrument method was selected as fast and to avoid the evaporation of mobile phase solvents, specific reservoir caps were also used.

Eight pharmaceutical assay methods were analyzed in the Alliance HPLC System with described conditions, and data was acquired as a typical quality control assay sequence. Six replicates of standard were made followed by six test sample injections, and bracketing standard were injected post test sample. Five to six such sample test sets were injected in each sequence and data was recorded as per individual method conditions.

Table 2. Percentage RSD values for methods run on the Alliance HPLC System.

Sr no.	Molecule	Sequence time (hrs)	Run time (min)	%RSD limit for area	Observed RSD with bracketing injections
1	Clopidogrel Bisulfate	17	25	1.0	0.7
2	Doxorubicin Hydrochloride	30	45	2.0	0.2
3	Galantamine	30	45	2.0	0.3
4	Irbesartan	24	35	2.0	0.6
5	Olmesartan	14	20	2.0	1.0
6	Clomipramine Hydrochloride	10	15	2.0	0.5
7	Aspirin	10	15	2.0	0.5
8	Dipyridamole	37	65	5.0	0.8




Figure 1. Plot shows observed % RSD values and % RSD limits for selected eight methods with described condition on Alliance System.

## CONCLUSIONS

The acquired data of each method was processed with a single processing method and results were generated. The results obtained for each method were compiled in Table 2. The relative standard deviation values of area for all of the eight methods were found to be well within the specified limit of system suitability test for respective method.

The Alliance HPLC System with 100 µL syringe and method specific precaution can be used for routine quality control analysis of the selected eight methods. Improved performance of the Alliance HPLC System demonstrated the system capability to address the system suitability criteria of area precision for eight challenging pharmacopoeial and non-pharmacopoeial assay methods.

## References

1. Hassan, Bassam Abdul Rasool. [HPLC Uses and Importance in the Pharmaceutical Analysis and Industrial Field](#). November 2012.

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, and Alliance are registered trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2017 Waters Corporation. Produced in the U.S.A. November 2017 720006125EN AG-PDF

Waters Corporation  
34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 1 508 478 2000  
F: 1 508 872 1990  
[www.waters.com](http://www.waters.com)